297 related articles for article (PubMed ID: 28490629)
21. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
[TBL] [Abstract][Full Text] [Related]
22. DNA polymerase ζ is a major determinant of resistance to platinum-based chemotherapeutic agents.
Sharma S; Shah NA; Joiner AM; Roberts KH; Canman CE
Mol Pharmacol; 2012 Jun; 81(6):778-87. PubMed ID: 22387291
[TBL] [Abstract][Full Text] [Related]
23. Rad18 guides poleta to replication stalling sites through physical interaction and PCNA monoubiquitination.
Watanabe K; Tateishi S; Kawasuji M; Tsurimoto T; Inoue H; Yamaizumi M
EMBO J; 2004 Oct; 23(19):3886-96. PubMed ID: 15359278
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib.
Morii I; Iwabuchi Y; Mori S; Suekuni M; Natsume T; Yoshida K; Sugimoto N; Kanemaki MT; Fujita M
Cancer Sci; 2019 Mar; 110(3):1044-1053. PubMed ID: 30648820
[TBL] [Abstract][Full Text] [Related]
25. The RAD6 DNA damage tolerance pathway operates uncoupled from the replication fork and is functional beyond S phase.
Karras GI; Jentsch S
Cell; 2010 Apr; 141(2):255-67. PubMed ID: 20403322
[TBL] [Abstract][Full Text] [Related]
26. Opposing effects of ubiquitin conjugation and SUMO modification of PCNA on replicational bypass of DNA lesions in Saccharomyces cerevisiae.
Haracska L; Torres-Ramos CA; Johnson RE; Prakash S; Prakash L
Mol Cell Biol; 2004 May; 24(10):4267-74. PubMed ID: 15121847
[TBL] [Abstract][Full Text] [Related]
27. MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.
Kfoury A; Le Corf K; El Sabeh R; Journeaux A; Badran B; Hussein N; Lebecque S; Manié S; Renno T; Coste I
J Natl Cancer Inst; 2013 Jul; 105(13):937-46. PubMed ID: 23766530
[TBL] [Abstract][Full Text] [Related]
28. PCNA Monoubiquitination Is Regulated by Diffusion of Rad6/Rad18 Complexes along RPA Filaments.
Li M; Sengupta B; Benkovic SJ; Lee TH; Hedglin M
Biochemistry; 2020 Dec; 59(49):4694-4702. PubMed ID: 33242956
[TBL] [Abstract][Full Text] [Related]
29. A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin.
Inoue A; Kikuchi S; Hishiki A; Shao Y; Heath R; Evison BJ; Actis M; Canman CE; Hashimoto H; Fujii N
J Biol Chem; 2014 Mar; 289(10):7109-7120. PubMed ID: 24474685
[TBL] [Abstract][Full Text] [Related]
30. A neomorphic cancer cell-specific role of MAGE-A4 in trans-lesion synthesis.
Gao Y; Mutter-Rottmayer E; Greenwalt AM; Goldfarb D; Yan F; Yang Y; Martinez-Chacin RC; Pearce KH; Tateishi S; Major MB; Vaziri C
Nat Commun; 2016 Jul; 7():12105. PubMed ID: 27377895
[TBL] [Abstract][Full Text] [Related]
31. Regulation of double-stranded DNA gap repair by the RAD6 pathway.
Moertl S; Karras GI; Wismüller T; Ahne F; Eckardt-Schupp F
DNA Repair (Amst); 2008 Nov; 7(11):1893-906. PubMed ID: 18722556
[TBL] [Abstract][Full Text] [Related]
32. Replication Fork Slowing and Reversal upon DNA Damage Require PCNA Polyubiquitination and ZRANB3 DNA Translocase Activity.
Vujanovic M; Krietsch J; Raso MC; Terraneo N; Zellweger R; Schmid JA; Taglialatela A; Huang JW; Holland CL; Zwicky K; Herrador R; Jacobs H; Cortez D; Ciccia A; Penengo L; Lopes M
Mol Cell; 2017 Sep; 67(5):882-890.e5. PubMed ID: 28886337
[TBL] [Abstract][Full Text] [Related]
33. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
34. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.
Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C
Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666
[TBL] [Abstract][Full Text] [Related]
35. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
Perego P; Gatti L; Caserini C; Supino R; Colangelo D; Leone R; Spinelli S; Farrell N; Zunino F
J Inorg Biochem; 1999 Oct; 77(1-2):59-64. PubMed ID: 10626355
[TBL] [Abstract][Full Text] [Related]
36. Regulation of DNA damage tolerance in mammalian cells by post-translational modifications of PCNA.
Kanao R; Masutani C
Mutat Res; 2017 Oct; 803-805():82-88. PubMed ID: 28666590
[TBL] [Abstract][Full Text] [Related]
37. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.
Yang J; Parsons J; Nicolay NH; Caporali S; Harrington CF; Singh R; Finch D; D'Atri S; Farmer PB; Johnston PG; McKenna WG; Dianov G; Sharma RA
Oncogene; 2010 Jan; 29(3):463-8. PubMed ID: 19838217
[TBL] [Abstract][Full Text] [Related]
38. RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
Somasagara RR; Spencer SM; Tripathi K; Clark DW; Mani C; Madeira da Silva L; Scalici J; Kothayer H; Westwell AD; Rocconi RP; Palle K
Oncogene; 2017 Nov; 36(48):6680-6690. PubMed ID: 28806395
[TBL] [Abstract][Full Text] [Related]
39. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells.
Voland C; Bord A; Péleraux A; Pénarier G; Carrière D; Galiègue S; Cvitkovic E; Jbilo O; Casellas P
Mol Cancer Ther; 2006 Sep; 5(9):2149-57. PubMed ID: 16985047
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and in vitro anticancer evaluation of some 4,6-diamino-1,3,5-triazine-2-carbohydrazides as Rad6 ubiquitin conjugating enzyme inhibitors.
Kothayer H; Spencer SM; Tripathi K; Westwell AD; Palle K
Bioorg Med Chem Lett; 2016 Apr; 26(8):2030-4. PubMed ID: 26965855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
